


## hDHODH-IN-13

|                    |   |       |          |
|--------------------|---|-------|----------|
| Cat. No.:          | HY-149642   |       |          |
| Molecular Formula: | C <sub>21</sub> H <sub>17</sub> ClFN <sub>5</sub> |       |          |
| Molecular Weight:  | 393.84  |       |          |
| Target:            | Dihydroorotate Dehydrogenase                      |       |          |
| Pathway:           | Metabolic Enzyme/Protease                         |       |          |
| Storage:           | Powder  | -20°C | 3 years  |
|                    | In solvent  | -80°C | 6 months |
|                    |   | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (317.39 mM; Need ultrasonic)

| Concentration             | Solvent | Mass      |            |            |
|---------------------------|---------|-----------|------------|------------|
|                           |         | 1 mg      | 5 mg       | 10 mg      |
| Preparing Stock Solutions | 1 mM    | 2.5391 mL | 12.6955 mL | 25.3910 mL |
|                           | 5 mM    | 0.5078 mL | 2.5391 mL  | 5.0782 mL  |
|                           | 10 mM   | 0.2539 mL | 1.2696 mL  | 2.5391 mL  |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC<sub>50</sub> value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD<sup>[1]</sup>.

### REFERENCES

[1]. Xia Zhou, et al. Discovery and Optimization of Novel h DHODH Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2023.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA